Literature DB >> 10815906

mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters.

A Haitel1, H G Wiener, U Baethge, M Marberger, M Susani.   

Abstract

The present study was designed to analyze the expression of p53 and mdm2 in clear cell renal cell carcinoma with special emphasis on their association with tumor grade and clinical outcome. In particular, the value of individual protein overexpression as well as combined p53/mdm2 positivity was evaluated because both proteins are functionally connected, and their expression is controlled by an autoregulatory feedback loop. A cohort of 97 clear cell renal cell carcinomas was analyzed. The overexpression of mdm2 and p53 proteins was investigated on paraffin-embedded material by using monoclonal antibodies. Eighteen tumors showed mdm2 positivity, whereas 35 of the tumors overexpressed p53. Whereas p53 and mdm2 positivity correlated significantly (P = 0.00004), no correlation could be found between mdm2 protein overexpression and tumor stage, lymph node involvement, and presence of distant metastases. mdm2 positivity was found significantly more frequently in tumors of higher grade. In univariate analysis, there was a statistically significant correlation between p53 and mdm2 overexpression in the same tumor and poor survival (P = 0.00179). Multivariate analysis revealed that coincident mdm2/p53 overexpression, the presence of distant metastases, and tumor grade were independent predictors for tumor progression. Our results indicate that mdm2/p53 co-overexpression, nuclear grade, and preoperative presence of distant metastasis are independent predictors for poor survival.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815906

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

1.  Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.

Authors:  Rit Vatsyayan; Jyotsana Singhal; Lokesh Dalasanur Nagaprashantha; Sanjay Awasthi; Sharad S Singhal
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

2.  Regulation of p53 and MDM2 activity by MTBP.

Authors:  Mark Brady; Nikolina Vlatkovic; Mark T Boyd
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

3.  Alterations in MDM2 expression in esophageal squamous cell carcinoma: relationship with p53 status.

Authors:  S Arora; R Mathew; M Mathur; T K Chattopadhayay; R Ralhan
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

4.  MDM2 regulates dihydrofolate reductase activity through monoubiquitination.

Authors:  Maria Maguire; Paul C Nield; Timothy Devling; Rosalind E Jenkins; B Kevin Park; Radoslaw Polański; Nikolina Vlatković; Mark T Boyd
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

5.  p53: a molecular marker for the detection of cancer.

Authors:  Mark T Boyd; Nikolina Vlatkovic
Journal:  Expert Opin Med Diagn       Date:  2008-09

Review 6.  p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Authors:  Aidan P Noon; Nikolina Vlatković; Radosław Polański; Maria Maguire; Howida Shawki; Keith Parsons; Mark T Boyd
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

7.  Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.

Authors:  Andrew M Roberts; Ian R Watson; Andrew J Evans; David A Foster; Meredith S Irwin; Michael Ohh
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

8.  The INK4a /ARF locus: role in cell cycle control for renal cell epithelial tumor growth after the Chernobyl accident.

Authors:  Alina Romanenko; Luisa Morell-Quadreny; Jose Antonio Lopez-Guerrero; Antonio Pellin; Valentin Nepomnyaschy; Alexander Vozianov; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2004-07-01       Impact factor: 4.064

9.  Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression.

Authors:  I Alldinger; K L Schaefer; D Goedde; L Ottaviano; U Dirksen; A Ranft; H Juergens; H E Gabbert; W T Knoefel; C Poremba
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-25       Impact factor: 4.553

10.  Immunohistochemical localization of mdm-2, p27Kip1 and bcl-2 in Warthin's tumor of the parotid gland.

Authors:  Ehab S Abd-Elhamid; Marwa M Elshafei
Journal:  Diagn Pathol       Date:  2009-05-16       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.